Health Trials

About this trial

Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect. Comparing the efficacy and safety differences between allogeneic platelet plasma and autologous platelet plasma is of significant importance and value for the clinical application.

Eligibility criteria

Qualifiers

The patient is aged 18-80 years old;

Diagnosed as type 1 or type 2 diabetes according to the World Health Organization standard, blood sugar has been controlled before enrollment, and the level of Glycated hemoglobin HbA1c is less than 10%;

Serum creatinine >106 μmol/L (men) or >97 μmol/L (women)

AND eGFR <90 mL/min/1.73m² (CKD-EPI) ；

Disqualifiers

Blood glucose is out of control or not yet effectively controlled，;

Severe diseases such as acute myocardial infarction, heart failure, hepatitis, shock, and respiratory failure have not been corrected yet;

Active bleeding inside the wound, and routine basic treatment plans cannot be implemented；

Uncontrolled systemic or disseminated infections;

Trial design

Treatments tested in this trial

  • allogeneic platelet plasma
  • autologous platelet plasma

Treatment groups

56 Participants
are divided into 2 treatment groups

Locations

1
Peking University Third Hospital100191, BeijingBeijing Municipality, China

Sponsors and collaborators

Peking University Third Hospital

Lead sponsor

Source ClinicalTrials.gov